Hyaluronic Acid Products from Genzyme, Sanofi-Aventis Preferred Among Orthopedic Surgeons, According to Survey (press release)
According to a comprehensive global survey of orthopedic surgeons conducted by iData Research (www.idataresearch.net), the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation (HA) treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.
Clinical efficacy and safety were rated as the most important factors in choosing a hyaluronic-acid brand world-wide, while pricing and reimbursement were more important in Asia and Latin-America than in the U.S. or Europe. Adoption of hyaluronic-acid for the treatment of knee osteoarthritis is expected to drive growth in the overall orthopedic biomaterials market in the U.S., Europe andAsia-Pacific, the combined markets for which were valued at over $5.8 billion in 2010.